{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:51:24Z","timestamp":1747183884309,"version":"3.40.5"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011369","name":"Royal Australian and New Zealand College of Ophthalmologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011369","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We assessed the proportion of eyes with neovascular age\u2010related macular degeneration (nAMD) in routine clinical practice that reach \u226514\u2009week treatment intervals and their outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We analysed data from the Fight Retinal Blindness! (FRB!) Project database, a prospectively designed registry of \u2018real\u2010world\u2019 outcomes. Treatment\u2010naive eyes starting vascular endothelial growth factor (VEGF) inhibitors for nAMD from 1st January 2006 were included. Eyes were defined to have reached the \u226514\u2009week treatment interval if they received \u22652 consecutive injections at treatment intervals of \u226514\u2009week but not exceeding 26\u2009weeks. Outcomes were reported in a subgroup of eyes that had 12\u2009months of follow\u2010up from reaching this interval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 3907 treatment\u2010na\u00efve eyes that started treatment during the identified periods on a treat\u2010and\u2010extend regimen and received at least 8 injections over the first 2\u2009years, 402 (10%) eyes received at least 2 consecutive injections at an interval of \u226514\u2009week during their follow\u2010up. Fifty\u2010two percent of these eyes maintained vision to 12\u2009months, however only 40% stayed at this interval and 25% of the lesions reactivated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found that only 10% of eyes with nAMD were extended beyond a 13\u2010week injection interval and that over half had returned to a shorter interval by 12\u2009months. Eyes that stayed at this extended treatment interval maintained stable vision. More data on the outcomes of eyes treated with intervals longer than 3\u00a0months are required to establish whether emerging VEGF inhibitors provide a more sustained effect than the currently available drugs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ceo.13962","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T12:57:11Z","timestamp":1623761831000},"page":"570-578","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neovascular age\u2010related macular degeneration at treatment intervals of 14\u2009weeks or greater"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-8811","authenticated-orcid":false,"given":"Elisa E.","family":"Cornish","sequence":"first","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-9803","authenticated-orcid":false,"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-6884","authenticated-orcid":false,"given":"Stephanie","family":"Young","sequence":"additional","affiliation":[{"name":"Gladesville Eye Specialists  Gladesville New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5646-9359","authenticated-orcid":false,"given":"Samantha","family":"Fraser\u2010Bell","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-4356","authenticated-orcid":false,"given":"Robyn","family":"Guymer","sequence":"additional","affiliation":[{"name":"Centre for Eye Research Australia University of Melbourne, Royal Victorian Eye and Ear Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-7100","authenticated-orcid":false,"given":"David","family":"Squirrell","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Auckland  Auckland New Zealand"},{"name":"Auckland District Health Board  Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-4991","authenticated-orcid":false,"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School  Sydney New South Wales Australia"},{"name":"Department of Ophthalmology University Hospital Zurich, University of Zurich  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-0274","authenticated-orcid":false,"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[{"name":"The University of Sydney, Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.01.024"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.05.024"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.09.004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.02.024"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.02.009"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.012"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","unstructured":"BergK PedersenTR SandvikL Bragad\u00f3ttirR.Comparison of ranibizumab and bevacizumab for neovascular age\u2010related macular degeneration according to LUCAS treat\u2010and\u2010extend protocol.2015;122(1):146\u2010152.","DOI":"10.1016\/j.ophtha.2014.07.041"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","unstructured":"FreundKB KorobelnikJ\u2010F DevenyiR et al.Treat\u2010and\u2010extend regimens with anti\u2010VEGF agents in retinal diseases retina.2015;35(8):1489\u20101506.","DOI":"10.1097\/IAE.0000000000000627"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0747-x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001496"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318296b271"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.04.012"},{"key":"e_1_2_7_16_1","article-title":"Prevalence and characteristics of macular atrophy in eyes with neovascular age\u2010related macular degeneration. A study from a long\u2010term observational dataset: the fight retinal blindness! Project","author":"Daien V","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002779"},{"volume-title":"R: A language and environmental for statistical computing","year":"2020","key":"e_1_2_7_18_1"},{"key":"e_1_2_7_19_1","unstructured":"TherneauTM.A package for survival analysis in S version 2.38 2015. Available from:https:\/\/CRAN.R-project.org\/package=survival."},{"key":"e_1_2_7_20_1","unstructured":"TherneauTM.coxme: Mixed effects Cox models R package version 2.2\u201016 2020. Available from:https:\/\/CRAN.R-project.org\/package=coxme."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v038.i08"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001142"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.023"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","unstructured":"GrunwaldJE PistilliM DanielE YingG\u2010S PanW JaffeGJ et al.Incidence and growth of geographic atrophy during 5\u2009years of comparison of age\u2010related macular degeneration treatments trials.2016.","DOI":"10.1016\/j.ophtha.2016.09.012"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","unstructured":"BhisitkulRB MendesTS RofaghaS et al.Macular atrophy progression and 7\u2010year vision outcomes in subjects from the ANCHOR MARINA and HORIZON studies: the SEVEN\u2010UP study.2015;159(5):915\u201024.e2.","DOI":"10.1016\/j.ajo.2015.01.032"},{"key":"e_1_2_7_26_1","article-title":"Dual angiopoietin\u20102 and VEGF\u2010A inhibition with faricimab in neovascular age\u2010related macular degeneration: phase 3 TENAYA and LUCERNE trial design","author":"Guymer R","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01309-9"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.13962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ceo.13962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.13962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T17:56:42Z","timestamp":1693331802000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.13962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/ceo.13962"],"URL":"https:\/\/doi.org\/10.1111\/ceo.13962","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"type":"print","value":"1442-6404"},{"type":"electronic","value":"1442-9071"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"2021-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}